(Q51912991)

English

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

scientific article published on 5 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. (English)

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

0 references

1 reference

based on heuristic

inferred from title

schizoaffective disorder

1 reference

based on heuristic

inferred from title

author name string

Raisa Andrezina

1

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Richard C Josiassen

2

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Ronald N Marcus

3

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Dan A Oren

4

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

George Manos

5

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Elyse Stock

6

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

William H Carson

7

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Taro Iwamoto

8

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

publication date

5 September 2006

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

Psychopharmacology

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

188

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

3

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

281-292

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

https://scigraph.springernature.com/pub.10.1007/s00213-006-0541-x

0 references

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating aggression in the psychiatric emergency service.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A rating scale for drug-induced akathisia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Managing the first episode of schizophrenia: the role of new therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calming versus sedative effects of intramuscular olanzapine in agitated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factor structure of the Agitated Behavior Scale.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An excitement subscale of the Positive and Negative Syndrome Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benzodiazepines in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A rating scale for extrapyramidal side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological treatment of psychotic agitation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16953381

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-006-0541-X

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

1 reference

Europe PubMed Central

17 April 2018

http://europepmc.org/abstract/MED/16953381

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51912991&oldid=1510085964"